1. A Neuro-oncologist’s Perspective on Management of Brain Metastases in Patients with EGFR Mutant Non-small Cell Lung Cancer
    Tresa McGranahan et al, 2017, Curr. Treat. Options in Oncol. CrossRef
  2. Single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma: a randomized open-label study
    Regina I. Jakacki et al, 2016, J Neurooncol CrossRef
  3. Clinical Efficacy of Afatinib Treatment for a Patient with Leptomeningeal Carcinomatosis
    Yo Kawaguchi et al, 2017, Chemotherapy CrossRef
  4. Stereotactic radiosurgery for small brain metastases and implications regarding management with systemic therapy alone
    Daniel M. Trifiletti et al, 2017, J Neurooncol CrossRef
  5. Recent developments in the chromatographic bioanalysis of approved kinase inhibitor drugs in oncology
    Johannes J.M. Rood et al, 2016, Journal of Pharmaceutical and Biomedical Analysis CrossRef
  6. Targeted Therapy for Brain Metastases in EGFR-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer
    Christina S. Baik et al, 2015, Journal of Thoracic Oncology CrossRef
  7. Current chemotherapeutic regimens for brain metastases treatment
    Joo Yeon Nam et al, 2017, Clin Exp Metastasis CrossRef
  8. Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity
    Yumie Yamanaka et al, 2017, Intern. Med. CrossRef
  9. Treatment of Leptomeningeal Metastases in a Patient with Non-Small Cell Lung Cancer Harboring EGFR T790M Mutation
    Hardy Niu et al, 2017, Case Rep Oncol CrossRef
  10. Brain Metastases from NSCLC: Radiation Therapy in the Era of Targeted Therapies
    Jonathan Khalifa et al, 2016, Journal of Thoracic Oncology CrossRef
  11. Translational gap in ongoing clinical trials for glioma
    Alecia Florence Guishard et al, 2017, Journal of Clinical Neuroscience CrossRef
  12. Current progress and outcomes of clinical trials on using epidermal growth factor receptor-tyrosine kinase inhibitor therapy in non-small cell lung cancer patients with brain metastases
    Ling-Ling Kong et al, 2017, Chronic Diseases and Translational Medicine CrossRef
  13. Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?
    Nicolas Girard, 2018, Future Oncology CrossRef
  14. Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease
    Maximilian Hochmair, 2018, Targ Oncol CrossRef
  15. Epidermal growth factor receptor (EGFR) T790M mutation identified in plasma indicates failure sites and predicts clinical prognosis in non-small cell lung cancer progression during first-generation tyrosine kinase inhibitor therapy: a prospective observational study
    Shirong Zhang et al, 2018, Cancer Commun CrossRef
  16. Targeting cancer's metabolic co-dependencies: A landscape shaped by genotype and tissue context
    Junfeng Bi et al, 2018, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer CrossRef
  17. An orthotopic glioblastoma animal model suitable for high-throughput screenings
    Linda Pudelko et al, 2018 CrossRef
  18. Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer
    William J. Kelly et al, 2018, Front. Oncol. CrossRef
  19. Efficacy and Safety of Radiotherapy Plus EGFR-TKIs in NSCLC Patients with Brain Metastases: A Meta-Analysis of Published Data.
    Xueyan Wang et al, 2018, Transl Oncol CrossRef
  20. Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer
    Po-Lan Su et al, 2018, Ther Adv Med Oncol CrossRef
  21. Combining genomic analyses with tumour-derived slice cultures for the characterization of an EGFR-activating kinase mutation in a case of glioblastoma
    Lea Loriguet et al, 2018, BMC Cancer CrossRef
  22. Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors
    Anna Wrona et al, 2018, Cancer Treatment Reviews CrossRef
  23. Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience
    Biagio Ricciuti et al, 2018, Ther Adv Respir Dis CrossRef
  24. Multidisciplinary expert opinion on the treatment consensus for patients with EGFR mutated NSCLC with brain metastases
    Santiago Ponce et al, 2019, Critical Reviews in Oncology/Hematology CrossRef
  25. Efficacy of afatinib, an irreversible ErbB family blocker, in the treatment of intracerebral metastases of non-small cell lung cancer in mice
    Shi-rong Zhang et al, 2017, Acta Pharmacol Sin CrossRef
  26. Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases
    Ronan Flippot et al, 2019, Journal of Thoracic Oncology CrossRef
  27. Assessing the Effectiveness of Systemic Therapy after Stereotactic Radiosurgery on Cancer Recurrence and All-Cause Mortality
    Timour Al-Khindi et al, 2019, World Neurosurgery CrossRef
  28. Brain MRI imaging characteristics predict treatment response and outcome in patients with de novo brain metastasis of EGFR-mutated NSCLC
    Chia-Ying Lin et al, 2019, Medicine CrossRef
  29. Combination of Whole-Brain Radiotherapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Improves Overall Survival in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases
    null Chen et al, 2019, Cancers CrossRef
  30. Molecularly targeted therapies for recurrent glioblastoma: current and future targets
    Darryl Lau et al, 2014, FOC CrossRef
  31. Adaptation to antiangiogenic therapy in neurological tumors
    Patrick M. Flanigan et al, 2015, Cell. Mol. Life Sci. CrossRef
  32. Safety of cranial radiotherapy concurrent with tyrosine kinase inhibitors in non-small cell lung cancer patients: A systematic review
    Lizza E.L. Hendriks et al, 2015, Cancer Treatment Reviews CrossRef
  33. The Continuation of Erlotinib Treatment in Non-Small Cell Lung Cancer Patients Whose Brain Lesion Is the Only Site of Progression: Prospective Pilot Study
    Kwai Han Yoo et al, 2015, Hanyang Med Rev CrossRef
  34. Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer
    Giulio Metro et al, 2015, Expert Opinion on Pharmacotherapy CrossRef
  35. Afatinib in Treatment-Naive Patients With EGFR-Mutated Lung Adenocarcinoma With Brain Metastasis
    Shih-Hong Li et al, 2015, Medicine CrossRef
  36. Oral Targeted Therapies and Central Nervous System (CNS) Metastases
    Michael P. Gabay et al, 2015, CNS Drugs CrossRef
  37. Novel Treatment Strategies for Brain Metastases in Non-small-cell Lung Cancer
    Nam Bui et al, 2016, Curr. Treat. Options in Oncol. CrossRef
  38. Activity of erlotinib when dosed below the maximum tolerated dose forEGFR-mutant lung cancer: Implications for targeted therapy development
    Benjamin L. Lampson et al, 2016, Cancer CrossRef
  39. Leptomeningeal carcinomatosis in non-small-cell lung cancer: initial response to erlotinib followed by relapse despite continuing radiological resolution of disease
    Alvin J. X. Lee et al, 2016, Oxf Med Case Rep CrossRef
  40. Integrating Domain Specific Knowledge and Network Analysis to Predict Drug Sensitivity of Cancer Cell Lines
    Sebo Kim et al, 2016, PLoS ONE CrossRef
  41. Systemic therapy of brain metastases: non–small cell lung cancer, breast cancer, and melanoma
    Marc C. Chamberlain et al, 2017, NEUONC CrossRef
  42. null
    Giuseppe Tridente, 2017 CrossRef
  43. Paradigm shift of therapeutic management of brain metastases in EGFR-mutant non-small cell lung cancer in the era of targeted therapy.
    Akimasa Sekine et al, 0 CrossRef
  44. Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study
    Yung-Hsuan Chen et al, 2019, BMC Cancer CrossRef
  45. A Multi-Modular System-Genetics (MMSG) Approach for Deep Representation Learning for Personalized Treatment of Cancer Using Sensitivity Analysis of Precision Drugs and Gene Expression Data
    Chiranjib Sur, 2019, Data-Enabled Discov. Appl. CrossRef
  46. Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
    Zong-Han Yao et al, 0 CrossRef
  47. Use of Systemic Therapy Concurrent With Cranial Radiotherapy for Cerebral Metastases of Solid Tumors
    Maikel Verduin et al, 2017, The Oncol CrossRef
  48. Therapeutic Drug Monitoring of Targeted Anticancer Protein Kinase Inhibitors in Routine Clinical Use
    Evelina Cardoso et al, 2020, Therapeutic Drug Monitoring CrossRef
  49. Impact of Use of Gastric-Acid Suppressants and Oral Anti-Cancer Agents on Survival Outcomes: A Systematic Review and Meta-Analysis
    Alice Indini et al, 2020, Cancers CrossRef
  50. Blood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy
    Yin-duo Zeng et al, 2015, Oncotarget CrossRef
  51. null
    Adam Lauko et al, 2020 CrossRef
  52. Barriers and opportunities for the clinical implementation of therapeutic drug monitoring in oncology
    Bradley D. Menz et al, 2020, Br J Clin Pharmacol CrossRef
  53. Safety and CSF distribution of high-dose erlotinib and gefitinib in patients of non–small cell lung cancer (NSCLC) with brain metastases
    Bharati Shriyan et al, 2020, Eur J Clin Pharmacol CrossRef
  54. Management of brain metastases according to molecular subtypes
    Riccardo Soffietti et al, 2020, Nat Rev Neurol CrossRef
  55. Novel Systemic Treatments for Brain Metastases From Lung Cancer
    Bicky Thapa et al, 2018, Curr Treat Options Neurol CrossRef
  56. Osimertinib rechallenge under steroid protection following osimertinib-induced pneumonitis: three case studies
    Christiane Bickert et al, 2021, Ther Adv Med Oncol CrossRef
  57. null
    Takeshi Kondoh et al, 2021 CrossRef
  58. Advances in targeted therapy in non‐small cell lung cancer with actionable mutations and leptomeningeal metastasis
    Ding Li et al, 2021, J Clin Pharm Ther CrossRef
  59. Brain metastases in patients with oncogenic-driven non-small cell lung cancer: Pros and cons for early radiotherapy
    Jiyun Lee et al, 2021, Cancer Treatment Reviews CrossRef
  60. null
    Emily F. Collier et al, 2021 CrossRef
  61. Craniospinal irradiation in the treatment of chemotherapy refractory leptomeningeal metastasis from breast cancer: A case report
    Daniel Tesolin et al, 2021, Cancer Reports CrossRef
  62. Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer
    Xueli Tian et al, 2021, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer CrossRef
  63. Complete remission in leptomeningeal metastasis of NSCLC with rare EGFR-SEPT14 fusion treated with osimertinib combined with intrathecal chemotherapy with pemetrexed
    Shengnan Zheng et al, 2022 CrossRef
  64. A Case Report of Recurrent L858R Mutation Non-Small-Cell Lung Cancer with Brain Metastases Treated with Erlotinib and Traditional Korean Medicine After Failure with Gefitinib
    Jung-min Yang et al, 2022, J Int Korean Med CrossRef
  65. Different Tyrosine Kinase Inhibitors Used in Treating EGFR-Mutant Pulmonary Adenocarcinoma with Brain Metastasis and Intracranial Intervention Have No Impact on Clinical Outcomes
    Chia-Yu Kuo et al, 2022, Cancers CrossRef
  66. A New Anticancer Semisynthetic Theobromine Derivative Targeting EGFR Protein: CADDD Study
    Ibrahim H. Eissa et al, 2023, Life CrossRef
  67. Therapeutic Monitoring of Orally Administered, Small-Molecule Anticancer Medications with Tumor-Specific Cellular Protein Targets in Peripheral Fluid Spaces—A Review
    Zoltán Köllő et al, 2023, Pharmaceutics CrossRef
  68. The role of targeted therapy and immune therapy in the management of non-small cell lung cancer brain metastases
    Cole Billena et al, 2023, Front. Oncol. CrossRef